Sanofi Consumer Healthcare India Posts 50%Profit Surge in Q4'25

Sanofi Consumer Healthcare India reported strong financial results for Q4’25 and the full year, highlighting steady momentum across domestic and export markets. The company’s performance reflects continued demand for its core portfolio and disciplined execution of its growth strategy.

In the fourth quarter, revenue rose 47% year-on-year to Rs. 2,510 million. Domestic sales increased 23%, while export sales surged 9.3 times compared to a low base last year. Profit after tax (PAT) climbed 50% to Rs. 665 million in Q4, signaling improved operating strength.

For the full year ended December 31, 2025, Sanofi Consumer Healthcare India posted revenue of Rs. 8,784 million, up 21% from FY’24. Annual PAT grew 33% to Rs. 2,401 million, supported by tighter cost control and a better product mix. The company also announced a dividend of Rs. 75 per share for FY’25.

Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future

Commenting on the quarterly results, Himanshu Bakshi, Managing Director, said: "This quarter’s performance emphasizes the strength of our core portfolio and the disciplined execution of our growth agenda. Our domestic business has delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from our export markets.”

Reflecting on FY’25 performance, Amit Jain, Chairman, added: "Our full-year performance reflects the strength of our strategy and the disciplined execution by our teams. By driving sustained growth, deepening penetration of our portfolio and accelerating digital transformation, we delivered meaningful outcomes for all our stakeholders. Our strong financial performance this year enables us to reward shareholders with a healthy dividend of Rs. 75 per share."